BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 23 of the 60 sources its claims cite were checked for support.
Abstract
Abstract B- and T-lymphocyte attenuator (BTLA) levels are increased in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). This condition is characterized by susceptibility to infection and T-cell immune exhaustion. However, whether BTLA can induce T-cell immune exhaustion and increase the risk of infection remains unclear. Here, we report that BTLA levels are significantly increased in the circulating and intrahepatic CD4 + T cells from patients with HBV-ACLF, and are positively correlated with disease severity, prognosis, and infection complications. BTLA levels were upregulated by the IL-6 and TNF signaling pathways. Antibody crosslinking of BTLA activated the PI3K-Akt pathway to inhibit the activation, proliferation, and cytokine production of CD4 + T cells while promoting their apoptosis. In contrast, BTLA knockdown promoted their activation and proliferation. BTLA -/- ACLF mice exhibited increased cytokine secretion, and reduced mortality and bacterial burden. The administration of a neutralizing anti-BTLA antibody reduced Klebsiella pneumoniae load and mortality in mice with ACLF. These data may help elucidate HBV-ACLF pathogenesis and aid in identifying novel drug targets.
Overview
CoChat Summary
TL;DR
BTLA is upregulated on circulating and liver-infiltrating CD4+ T cells in HBV-ACLF and is linked to disease severity, infection, and poor prognosis. The paper shows that BTLA drives CD4+ T-cell exhaustion, and that genetic or antibody-mediated BTLA blockade improves immune function and reduces bacterial burden and mortality in mouse models.
Key findings
- In HBV-ACLF patients, BTLA expression on peripheral blood CD4+ T cells was significantly increased, and it was also increased on liver-infiltrating CD4+ T cells; BTLA levels on CD4+ T cells were positively correlated with Child-Pugh, MELD, CLIF-SOFA, CLIF-C ACLFs, and COSSH-ACLF scores.
- The discussion reports that 61.39% of HBV-ACLF patients developed bacterial infections during hospitalization, and the Results state that BTLA expression was higher in co-infected patients than in non-infected patients.
- In patient samples, BTLA-high CD4+ T cells showed an exhausted phenotype: BTLA crosslinking suppressed CD25, CD38, and CD69, reduced IFN-γ, IL-2, and TNF-α production, reduced proliferation, and promoted apoptosis; BTLA shRNA reversed these effects.
- In mouse ACLF models, BTLA-/- mice had higher CD4+ T-cell cytokine output and lower mortality/bacterial burden; a neutralizing anti-BTLA antibody reduced Klebsiella pneumoniae load and mortality, and in the ConA+CLP sepsis model BTLA-/- mice had lower mortality and bacterial DNA in blood.
Methods
- Human study: blood from 104 CHB patients, 101 patients with severe liver injury, and 90 healthy controls; liver tissue from 5 hemangioma, 5 CHB, and 7 HBV-ACLF patients; among the severe liver injury group, 71 were HBV-ACLF.
- Main assays: flow cytometry and immunofluorescence for BTLA/HVEM expression, cytokine measurements, shRNA knockdown and agonistic anti-BTLA crosslinking in CD4+ T cells, RNA-seq, RT-PCR, and western blotting for pathway analysis.
- Animal work: WT and BTLA-/- C57BL/6 mice were used in ConA-induced ACLF, CCl4-induced ACLF, and CLP/K. pneumoniae infection models; outcomes included cytokines, bacterial load, pathology, and survival.
Limitations
- Not stated in the paper.
- Evident from the text: the mechanistic pathway work is based largely on ex vivo cell assays and mouse models, so direct causal confirmation in patients is not shown.
- Evident from the text: some cohorts are relatively small for tissue analyses (e.g., 5 hemangioma, 5 CHB, 7 HBV-ACLF liver samples), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
16 Valid · 1 Not valid · 20 Not checked · 104 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The inappropriate CARS may cause the dysfunction and exhaustion of both innate and adaptive immune responses and decrease their ability to remove pathogens, a phenomenon known as immune exhaustion (or immune paralysis)5.”
§ BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion > Introduction
What the sources say
- Partly supportedcites [5] Martin-Mateos R Alvarez-Mon M Albillos A Dysfunctional Immune Response in acute-on-chronic liver failure: it takes two to tango Front. Immunol. 2019 10 973 10.3389/fimmu.2019.00973 31118937 PMC6504833 sourceExperimental — accuracy not yet measured
The Abstract and “Immune System Cell Paralysis in ACLF” section say that excessive compensatory anti-inflammatory response, together with immune-cell exhaustion and dysfunction, leads to immune paralysis and a compromised response against pathogens. They do not say that the compensatory response itself causes the exhaustion, as the citing sentence suggests. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“BTLA-deficient mice have exhibited enhanced pathogen clearance compared to wild-type (WT) mice in the early phase of infection”
§ BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion > Introduction
What the sources say
- Supportedcites [15] Sun Y B and T lymphocyte attenuator tempers early infection immunity J. Immunol. 2009 183 1946 1951 10.4049/jimmunol.0801866 19587015 PMC2895307 source
The Results section reports significantly reduced Listeria monocytogenes bacterial loads in the spleens and livers of BTLA-deficient mice compared with wild-type mice. It also reports differences in clearance as early as day 1 after infection, supporting the claim about the early phase. (LLM, conf=0.93)
- Supportedcites [16] Kobayashi Y B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells Proc. Natl. Acad. Sci. USA 2013 110 5121 5126 10.1073/pnas.1222093110 23479601 PMC3612598 source
The Introduction/abstract of our copy states the claim directly: 'Recently, several studies have reported that BTLA-deficient (BTLA -/-) mice show enhanced pathogen clearance compared with WT mice in early phase of infections' (p. 1, abstract/introduction passage), and the introduction elaborates it with the supporting studies (Sun et al., bacterial clearance in the early phase; Shubin et al., survival after cecal ligation and puncture; Adler et al., parasite clearance before acquired immunity) (Introduction, p. 1-2), reiterated in the Discussion ('BTLA -/- mice have been reported to exhibit significantly higher pathogen clearance compared with WT mice'). The citing sentence is a hedged/perfect-tense summary of reported findings rather than a claim that this paper performed the pathogen-clearance experiments, so the paraphrase matches what the source attributes and relies on. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the inclusion criteria of ACLF agreed with the North American Consortium for the Study of End-stage Liver Disease (NACSELD)19 and the EASL-CLIF20 standards, the results also showed that BTLA was highly expressed on CD4+ T cells (but not on CD8+ T cells) from patients with HBV-ACLF”
§ BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion > Results > Expression of BTLA on CD4+ T cells and HVEM on dendritic cells (DC) is elevated synchronously in HBV-ACLF
What the sources say
- Supportedcites [19] Bajaj JS Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures Hepatology 2014 60 250 256 10.1002/hep.27077 24677131 PMC4077926 source
Citation 19 is attached to the NACSELD standards, not to the citing authors’ BTLA results. The source’s Abstract > Results defines infection-related ACLF as two or more organ failures, supporting its use as the NACSELD criteria reference. No page number is available in our copy. (LLM, conf=0.91)
- Could not verifycites [20] Pan HC Scoring systems for 6-month mortality in critically ill cirrhotic patients: a prospective analysis of chronic liver failure - sequential organ failure assessment score (CLIF-SOFA) Aliment Pharmacol. Ther. 2014 40 1056 1065 10.1111/apt.12953 25208465 sourceExperimental — accuracy not yet measured
Our copy of Pan et al. 2014 is a single-centre prospective validation of prognostic scores (CLIF-SOFA, SOFA, APACHE II/III, Child-Pugh, MELD) for 6-month mortality in 250 critically ill cirrhotic patients; it reports only clinical/biochemical variables and no immunological measurements. Searches for 'BTLA expression CD4+ T cells HBV-ACLF', 'T lymphocyte exhaustion / flow cytometry marker expression' and 'NACSELD ACLF criteria' returned only scoring-definition, patient-data and discussion passages — no passage addresses BTLA or T-cell subset expression, and NACSELD is not mentioned (the EASL-CLIF reference, ref. 17, appears only as the origin of the CLIF-SOFA definition, Introduction). The paper neither supports nor contradicts the claimed T-cell finding, so the attribution cannot be checked against our copy. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
§ BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion > Results > BTLA may activate the phosphoinositide-3-kinase/Akt/glycogen synthase kinase-3 (PI3K-Akt-GSK-3β) pathway to induce CD4+T-cell exhaustion
What the sources say
- Not checked — no full text of the sourcecites [11] Watanabe N BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 Nat. Immunol. 2003 4 670 679 10.1038/ni944 12796776 source
- Partly supportedcites [14] Yu X Zheng Y Mao R Su Z Zhang J BTLA/HVEM signaling: milestones in research and role in chronic hepatitis B virus infection Front. Immunol. 2019 10 617 10.3389/fimmu.2019.00617 30984188 PMC6449624 sourceExperimental — accuracy not yet measured
The ‘Structure and Distribution of BTLA’ section (page unavailable) says BTLA’s inhibitory motif binds and activates SHP-1 and SHP-2, which inhibit cell activation. It does not say that anti-BTLA crosslinking causes phosphorylation of those phosphatases. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies have shown that CCl4 combined with LPS or Klebsiella pneumoniae (K.P.) injection can induce a mouse model of ACLF15,28,29.”
§ BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion > Results > BTLA contributes to CD4+ T-cell immune exhaustion and increased mortality and infection rates in the ACLF model induced by carbon tetrachloride (CCl4)
What the sources say
- Could not verifycites [15] Sun Y B and T lymphocyte attenuator tempers early infection immunity J. Immunol. 2009 183 1946 1951 10.4049/jimmunol.0801866 19587015 PMC2895307 sourceExperimental — accuracy not yet measured
The Materials and Methods section describes a Listeria monocytogenes infection model, not a mouse model of acute-on-chronic liver failure. Searches for CCl4, LPS, Klebsiella pneumoniae, and acute-on-chronic liver failure found no passage addressing the claimed induction method; the copy has no page numbers. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [28] Engelmann C Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure J. Hepatol. 2020 73 102 112 10.1016/j.jhep.2020.01.011 31987990 source
- Partly supportedcites [29] Xiang X Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice J. Hepatol. 2020 72 736 745 10.1016/j.jhep.2019.11.013 31786256 PMC7085428 sourceExperimental — accuracy not yet measured
The Introduction describes existing ACLF mouse models using chronic CCl4 injury followed by D-galactosamine/LPS, and the Results describe the authors’ model using chronic CCl4, an acute double dose of CCl4, and K. pneumoniae. Thus the paper supports both types of model, but the claim omits the additional acute-injury treatment required in each; it does not establish that CCl4 with LPS or K. pneumoniae alone induces ACLF. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
80 more claims · 2 with their cited sources checked
Create a free account to see all 141 claims and to verify the 12 references still open.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 41
- The quote only partly states this claim. 1
Citations
Cites
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“The MFI of BTLA expression on CD4 + T cells exhibited positive correlations with various disease severity indicators, including Child-Pugh scores 21 , model for end-stage liver disease (MELD) scores 22 , CLIF-Sequential Organ Failure Assessment (SOFA) 20 , CLIF-C ACLFs 23 , and Chinese Group on the…”
BackgroundWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“…+ T-celldifferentiationtoeffectorcytotoxicTcells;(2)CD4 + T cells are the main source of IL-10 and IL-21, which contribute to sustaining antiviral CD8 + T cells during chronic infection 35 ; and (3) CD4 + T cells have more functional properties and differentiation potential than CD8 + T cells 35 .”
BackgroundAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
The model for end-stage liver disease (MELD)
Kamath, P. S., & Kim, R. W. (2007) · Hepatology · doi:10.1002/hep.21563 · Cited by 1,674
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Jalan, R., Saliba, F., Pavesi, M., Amoros, A., Moreau, R., Ginès, P., Levesque, E., Durand, F., Angeli, P., Caraceni, P., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.06.012 · Cited by 1,032
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02844-06 · Cited by 920
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 2×
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with fi ndings from previous studies 11,42 , and also activates the PI3K-Akt-GSK-3 β pathway in puri fi ed CD4 + T cells.”
BackgroundMethodBajaj, J. S., O'Leary, J. G., Reddy, R. K., Wong, F., Biggins, S. W., Patton, H., Fallon, M. B., Garcia-Tsao, G., Maliakkal, B., Malik, R., et al. (2014) · Hepatology · doi:10.1002/hep.27077 · Cited by 574
Research works printed but not linked: 2
- Zhang N Establishment of model of dynamic change of immune status of ACLF induced by ConA repeated administration in mice. Chin. J. Gastroenterol. 2016 21 326 330
- Mann P. C. International Specification for Terminology and Diagnostic Criteria for Pathological Changes in Rats and Mice (INHAND) (Beijing: China Agriculture Press, 2019).
Cited by
Tong, J., Tan, Y., Ouyang, W., & Chang, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00636-5 · Cited by 47
Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
Sarin, S. K., Choudhury, A. K., Kumar, A., Mahmud, N., Lee, G. H., Ning, Q., Tan, S.-S., Thanapirom, K., Arora, V., Nakayama, N., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01159-4 · Cited by 39
Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression
Liang, X., Luo, J., Zhou, Q., Xin, J., Li, J., Peng, B., Hu, M., Jiang, J. T., Qiang, W., Li, P., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333308 · Cited by 36
Self-citationCytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets
Lai, L., Ran, S., Li, Y., Cui, J., Zhang, X., Yu, J., Zou, Y., Cheng, Z., Xia, J., & Wu, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02533-z · Cited by 29
Self-citationEmerging mRNA Technology for Liver Disease Therapy
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 21
Metadata
- Authors
- Yu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., Zhang, S., Long, J., Zhu, M., Zhang, X., Wu, J., Ma, Z., Zhu, H., Su, M., Xu, J., Li, B., Mao, R., Su, Z., & Zhang, J.
- Affiliations
- Fujian Medical University (CN)
- Fudan University (CN)
- Dali University (CN)
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Yu, Xueping
- Mao, Richeng
- Su, Zhijun
- Zhang, Jiming
- ORCID
- Venue
- Nature Communications
- Published
- 2024-02-28
- Volume
- 15
- Issue
- 1
- Pages
- 1835-1835
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10901893
- OpenAlex
- W4392231520
- Cited by
- 47
- References
- 48
- Citations by year
- 2026: 23 · 2025: 22 · 2024: 2
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Greater South Information System
- Funders
- National Natural Science Foundation of China (82370604, 82372237, ZD2021CY001, 82160361, 2017ZX10202203-007, 81670528, 82003864, 2017ZX10202203, 2017ZX10202202)
- Natural Science Foundation of Fujian Province (2023J01239, 2019J01593)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- BTLA, acute-on-chronic liver failure, hepatitis B virus, CD4+ T cell exhaustion, infection susceptibility, Klebsiella pneumoniae, bacterial infection, IL-6 signaling, TNF signaling, PI3K/Akt signaling, T cell apoptosis
- MeSH terms
- T-Cell Exhaustion, Animals, Humans, Receptors, Immunologic, CD4-Positive T-Lymphocytes, Cytokines, Hepatitis B, Chronic, Phosphatidylinositol 3-Kinases, Mice, Acute-On-Chronic Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion. https://app.cochat.ai/papers/10.1038/s41467-024-46047-8
- The paper
- Yu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., Zhang, S., Long, J., Zhu, M., Zhang, X., Wu, J., Ma, Z., Zhu, H., Su, M., Xu, J., . . . Zhang, J. (2024). BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion. Nature Communications. https://doi.org/10.1038/s41467-024-46047-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.